.Zevra Therapies’ rare disease drug seems to be on the pathway to authorization this loss after getting the backing of an FDA advising board, although
Read moreBicara, Zenas look for IPOs to push late-phase resources toward market
.Bicara Therapies and Zenas Biopharma have actually provided fresh catalyst to the IPO market along with filings that explain what recently public biotechs might appear
Read more‘ All palms on deck’ at Lilly as peers target obesity market
.Chief executive officer David Ricks may view the providers establishing outdoors tents at basecamp responsible for Eli Lilly in an effort to receive a footing
Read more8 months after a $213M fundraise, genetics publisher Volume creates cuts
.After increasing $213 thousand in 2023– one of the year’s most extensive exclusive biotech rounds– Tome Biosciences is producing decreases.” Despite our crystal clear clinical
Read more3 biotechs attempt to trump the summer season warmth through shedding staff
.As biotechs attempt to transform a new webpage in August, a minimum of three companies have shed personnel in efforts to create on. First off
Read more2 cancer cells biotechs merge, making global impact
.OncoC4 is taking AcroImmune– and its internal medical manufacturing capacities– under its own fly an all-stock merging.Each cancer cells biotechs were actually co-founded through OncoC4
Read moreZephyrm seeks Hong Kong IPO to money period 3 cell therapy trials
.Zephyrm Bioscience is actually gusting towards the Hong Kong stock exchange, submitting (PDF) for an IPO to bankroll phase 3 trials of its own cell
Read moreZenas, MBX, Bicara head to Nasdaq in very hot time for biotech IPOs
.It is actually an uncommonly occupied Friday for biotech IPOs, along with Zenas BioPharma, MBX and Bicara Therapeutics all going public with fine-tuned offerings.Of today’s
Read moreZenas, Bicara laid out to raise $180M-plus in separate IPOs
.After uncovering programs to attack the U.S. social markets lower than a month ago, Zenas Biopharma as well as Bicara Therapies have mapped out the
Read moreZenas, Bicara laid out to raise $180M-plus in separate IPOs
.After uncovering programs to attack the U.S. social markets lower than a month ago, Zenas Biopharma as well as Bicara Therapies have mapped out the
Read more